Fig. 4
In vivo efficacy of D2C7-IT+αCTLA-4/αPD-1 combination therapies in subcutaneous CT-2A-dmEGFRvIII-Luc tumor-bearing C57BL/6 J mice. (a) Survival curves for groups 1–6 (G1–6) followed up to Day 35 and (b) Groups 4–6 (G4–6) followed up to Day 62 after initial tumor inoculation are presented as SEM. (c) Survival curves are presented as SEM for mice surviving symptom-free to Day 72 post-tumor implantation from different treatment groups and were re-challenged initially in the left flank with 1 × 106 CT-2A parental cells. C57BL/6 J mice (N = 5) were used as naïve controls. (d) Mice surviving symptom-free from different treatment groups after first re-challenge underwent a second re-challenge with 3 × 105 CT-2A-dmEGFRvIII-Luc cells in the brain on Day 126. C57BL/6 J mice (N = 5) were used as naïve controls. Median survival estimates are presented